Intestinal LSS deficiency ameliorates MASLD by activating a metabolic-immune-dependent gut barrier

Acta Universitatis Medicinalis Anhui     font:big middle small

Fund programs: Natural Science Foundation of Anhui Province (No. 2108085MH266)

Authors:Wang Zihan, Bai Hongmei, He Qingya, Zhou Wenjing, Zhong Jian, Jiang Xiaoli, Zhang Sumei, Zhang Shengquan

Keywords:MASLD; LSS; gut-liver axis; cholesterol absorption; gut immunity; fatty liver model

DOI:专辑:医药卫生科技

〔Abstract〕 Objective To investigate whether intestinal deficiency of lanosterol synthase (LSS), a key enzyme in cholesterol synthesis, influences the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) by regulating intestinal cholesterol absorption and immune response. Methods LSS heterozygous knockout (LSS+/-) mice and wild-type (WT) controls were generated using CRISPR/Cas9 technology and fed either a high-fat diet (HFD) or regular chow (CHOW). The model was validated by genotyping. Hepatic steatosis was assessed by H&E and Oil Red O staining. Immunohistochemistry was used to detect the localization and expression of NPC1L1 and CD36 proteins in the intestine. Western blot analysis was performed to measure JNK phosphorylation and TLR4 protein levels in intestinal tissues. Real-time quantitative polymerase chain reaction (qPCR) was employed to examine the mRNA expression of TLR4 and IL-6. Results LSS+/- mice were successfully validated by genotyping and reduced intestinal LSS protein expression. H&E and Oil Red O staining of liver sections showed that, compared with WT mice fed a CHOW diet, WT mice fed a HFD exhibited a marked increase in hepatic lipid vacuoles. In contrast, compared with HFD-fed WT mice, HFD-fed LSS+/- mice displayed significantly attenuated hepatic lipid deposition and reduced serum ALT levels (P<0.05). Immunohistochemical analysis revealed that, compared with WT mice, the expression of the cholesterol absorption protein NPC1L1 in the intestinal villi of LSS+/- mice was downregulated under both CHOW and HFD conditions (P<0.001 for HFD group). Conversely, the expression of the fatty acid transporter CD36 was upregulated in the intestines of LSS+/- mice (P < 0.05 for CHOW group, P<0.01 for HFD group). Western blot analysis demonstrated that, compared with WT mice, TLR4 protein expression in the intestines of LSS+/- mice significantly increased under both CHOW and HFD conditions (P < 0.05 for CHOW group, P < 0.05 for HFD group). JNK phosphorylation level was significantly elevated in LSS+/- mice under CHOW condition (P < 0.05). Under HFD condition, total JNK protein expression increased, but its phosphorylation level showed no significant change. qPCR analysis showed that, compared with WT mice, the mRNA levels of TLR4 (P<0.01 for CHOW group, P<0.000 1 for HFD group) and IL-6 (P<0.001 for CHOW group, P<0.01 for HFD group) were significantly upregulated in the intestines of LSS+/-mice. Conclusion LSS deficiency counteracts hepatic lipid deposition by orchestrating a synergistic reprogramming involving restricted intestinal cholesterol absorption, enhanced fatty acid utilization, and activation of immune pathways, suggesting intestinal LSS as a potential therapeutic target of MASLD.